Please select the option that best describes you:
What factors do you use when considering the addition of celecoxib to adjuvant chemotherapy for patients with stage III colon cancer, given CALGB/SWOG 80702 trial results?
Are you adopting this approach for all patients, patients with PI3K mutations, or none?
Answer from: Medical Oncologist at Community Practice
Based on the 80702 results, I have started checking for PI3K mutations. In patients with tumors that have a PI3K mutation, I especially recommend celecoxib or aspirin for secondary prevention. However, there are separate data that aspirin may be helpful for primary prevention of polyp formation. Thu...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Since CALGB/SWOG 80702 did not show a benefit from adding celecoxib to adjuvant therapy, I do not recommend its use for all patients. However, subsequent analyses suggest that celecoxib may provide benefit in patients with positive ctDNA or PIK3CA mutations, though these findings require validation....